Vanguard Group Inc Aligos Therapeutics, Inc. Transaction History

Vanguard Group Inc

$4.96 Trillion
Q1 2024

A detailed history of Vanguard Group Inc transactions in Aligos Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,013,067 shares of ALGS stock, worth $699,016. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,013,067

Previous 1,011,651 0.14%

Holding current value

$699,016

Previous $667,000 48.73%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$0.64 - $1.13 $906 - $1,600	1,416 Added 0.14%	1,013,067 $992,000
Q4 2023 Feb 14, 2024	BUY	$0.56 - $0.8 $579 - $827	1,034 Added 0.1%	1,011,651 $667,000
Q3 2023 Nov 14, 2023	BUY	$0.71 - $1.06 $11,292 - $16,859	15,905 Added 1.6%	1,010,617 $757,000
Q2 2023 Aug 14, 2023	SELL	$0.89 - $1.36 $19,552 - $29,877	-21,969 Reduced 2.16%	994,712 $964,000
Q1 2023 May 15, 2023	BUY	$0.87 - $2.11 $2,770 - $6,720	3,185 Added 0.31%	1,016,681 $884,000

Q4 2022 Feb 10, 2023	SELL	$0.89 - $1.08 $68,081 - $82,615	-76,496 Reduced 7.02%	1,013,496 $962,000
Q3 2022 Nov 14, 2022	BUY	$1.06 - $1.6 $28,959 - $43,712	27,320 Added 2.57%	1,089,992 $1.2 Million
Q2 2022 Aug 12, 2022	SELL	$1.04 - $2.14 $230,974 - $475,274	-222,091 Reduced 17.29%	1,062,672 $1.29 Million
Q1 2022 May 13, 2022	SELL	$2.08 - $12.2 $187,514 - $1.1 Million	-90,151 Reduced 6.56%	1,284,763 $2.76 Million
Q4 2021 Feb 14, 2022	BUY	$11.48 - $17.69 $1.14 Million - $1.76 Million	99,699 Added 7.82%	1,374,914 $16.3 Million
Q3 2021 Nov 12, 2021	BUY	$14.57 - $17.72 $4.25 Million - $5.17 Million	291,919 Added 29.69%	1,275,215 $19.8 Million
Q2 2021 Aug 13, 2021	BUY	$20.3 - $33.6 $20 Million - $33 Million	983,296 New	983,296 $20 Million

Others Institutions Holding ALGS

# of Institutions

Shares Held

46.2M

Call Options Held

6.11M

Put Options Held

200

View Full List

About Aligos Therapeutics, Inc.

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $27.4M
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

More about ALGS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Aligos Therapeutics, Inc. Transaction History